Allogenic transplantation of the bone marrow after regimens of low-intensity conditioning in therapy of patients with hemoblastoses

Terapevticheskii Arkhiv

Volumn 75, Issue 7, 2003, Pages 15-21

  Demidova, I A ^a   Savchenko, V G ^a   Olshanskaya, Yu V ^a   Poreshina, L P ^a   Kutyina, R M ^a   Surin, V L ^a   Misyurin, A V ^a   Domracheva, E V ^a   Parovichnikova, E N ^a  

^a NONE

Author keywords

Bone marrow transplantation; Hemopoietic chimerism; Minimal residual disease

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MYELOMONOCYTIC LEUKEMIA; REMISSION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 2142727311     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rizzo J. D. New summary slides show current trends in BMT. ABMTR Newsletter 1998; 5 (1): 4-10.
2. Barrett A. J. Mechanisms of graft-versus-leukemia reaction. Stem Cells 1997; 15: 248-258.
3. Giralt S., Eatey E., Korbling M. et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
4. Khouri I. F., Keating M., Korbling M. et al. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancy. J. Clin. Oncol. 1998; 16: 2817-2824.
5. Slavin S., Nagler A., Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
6. Carella A. M., Giralt S., Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000; 85: 304-313.
7. Boerwinkle E., Xiang W., Fourest E. et al. Rapid typing of tandemly repeated hypervariable loci by the PCR. Application to the apolipoprotein B3 HVR region. Proc. Natl. Acad. Sci. USA 1989; 86: 212-216.
8. Horn G. T., Richards B., Klinger K. W. Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction. Nucleic Acids Res. 1989; 17 (5): 2140.
9. Mitelman G., ed. ISCN (1995) Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
10. van Dongen J. J. M., Macyntire E. A., Gabert J. A. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13 (12): 1901-1928.
11. Spitzer T. R. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000; 5: 215-223.
12. Carella A. M., Champlin R., Slavin S. et al. Mini-allografts: ongoing trials in s humans. Bone Marrow Transplant. 2000; 25: 345-350.
13. Jatunen E., Myllykangas-Luosujarvi R. Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives. Bone Marrow Transplant. Ibid. 22: 351-356.
14. Kapelushnik J., Or R., Slavin S. A fludarabine-based protocol for bone-marrow transplantation in Fanconi's anemia. Bone Marrow Transplant. Ibid. 1997; 20: 1109-1110.
15. McSweeny P., Neiderweiser D., Shizuru J. et al. Outpatient allografting with minimal myelosuppressive, immunosuppressive conditioning of low-dose TBI and post-grafting cyclosporine (CSP) and mycophenolate mofetil (MMF). Blood 1999; 94: 39a.
16. Spitzer T. R., McAfee S., Sackstein R. et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematological malignancies. Biol. Blood Bone Marrow Transplant. 2000; 6: 309-320.
17. Pelot M. R., Pearson D. A., Swenson K. et al. Lymphohematopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphomide-based nonmyeloablative conditioning regimen. Biol. Blood Bone Marrow Transplant. Ibid. 1999; 5: 133-135.
18. Childs R., Clave E., Contentin N. et al. Reduced toxicity and transplant-related mortality (TRM) following non-myeloablative allogeneic peripheral blood stem cell transplantation for malignant disease. Blood 1999; 94: 3234-3241.
19. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. In: 55th Annual meeting: ASCO: Educational Book. 1999. 241.